China Dasheng Biotechnology Company (CDBT)

CDBT Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2008	FY 2007	FY 2006
Period Ending	Mar 31, 2009	Jun 30, 2008	Jun 30, 2007	Jun 30, 2006
Revenue	20.95	16.29	9.96	7.35
Revenue Growth (YoY)	45.16%	63.57%	35.52%	-
Cost of Revenue	10.93	8.79	5.83	4.11
Gross Profit	10.02	7.5	4.13	3.25
Selling, General & Admin	2.76	2.2	1.4	1.36
Other Operating Expenses	0.23	0.23	-0.02	-
Operating Expenses	2.99	2.43	1.38	1.36
Operating Income	7.04	5.07	2.75	1.89
Interest Expense	-0.01	-0.04	-0.09	-0.07
Interest & Investment Income	0.24	0.16	-	-
Other Non Operating Income (Expenses)	0.06	-	-	0.02
Pretax Income	7.33	5.19	2.66	1.84
Earnings From Continuing Operations	7.33	5.19	2.66	1.84
Minority Interest in Earnings	-0.92	-0.55	-0.67	-0.34
Net Income	6.41	4.64	1.99	1.5
Net Income to Common	6.41	4.64	1.99	1.5
Net Income Growth	96.13%	132.90%	32.78%	-
Shares Outstanding (Basic)	30	30	32	32
Shares Outstanding (Diluted)	30	30	32	32
Shares Change (YoY)	-6.48%	-6.48%	-	-
EPS (Basic)	0.21	0.15	0.06	0.05
EPS (Diluted)	0.21	0.15	0.06	0.05
EPS Growth	109.73%	149.05%	32.79%	-
Free Cash Flow	8.34	4.07	0.33	-0.81
Free Cash Flow Per Share	0.28	0.14	0.01	-0.03
Gross Margin	47.85%	46.05%	41.45%	44.16%
Operating Margin	33.59%	31.15%	27.61%	25.65%
Profit Margin	30.58%	28.47%	19.99%	20.40%
Free Cash Flow Margin	39.79%	24.96%	3.35%	-11.05%
EBITDA	7.72	5.7	3.27	2.31
EBITDA Margin	36.86%	34.99%	32.85%	31.44%
D&A For EBITDA	0.69	0.63	0.52	0.43
EBIT	7.04	5.07	2.75	1.89
EBIT Margin	33.59%	31.15%	27.61%	25.65%
Advertising Expenses	-	-	-	0.13

Updated May 14, 2009. Source: S&P Global Market Intelligence. Standard template. Financial Sources.